http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&p=irol-newsArticle&ID=1784054&highlight=
NEWARK, Calif., Feb 12, 2013 (GLOBE NEWSWIRE via COMTEX) — StemCells, Inc. STEM -4.52% today announced that the twelve-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable